We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

1030:HKEXSeazen Group Limited Analysis

Data as of 2026-03-17 - not real-time

HK$2.24

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Seazen Group is trading at HKD 2.24, just above its calculated support of 2.15 and well below the resistance of 2.51. The price sits under the 20‑day, 50‑day and 200‑day moving averages (2.30, 2.31, 2.34), the MACD line is negative and the histogram is shrinking, and the RSI sits at 44.7, signalling a lack of bullish momentum. Volume has been on a downtrend and 30‑day volatility is elevated at 58.5%, while the computed beta is near zero, indicating the stock moves largely independent of the broader market.
Fundamentally, the stock carries a trailing PE of 74.7 versus an industry average of 33.1, yet the forward PE collapses to 11.6, and the price‑to‑book ratio is only 0.30, suggesting a potential valuation disconnect. Revenue has contracted by 34.8% and margins are thin, with a debt‑to‑equity of nearly 70, while operating cash flow remains negative. No dividend is paid, but analysts (9) rate the stock as a Buy with a median target near 3.16, implying upside of roughly 33% if the price recovers.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish technical indicators (price below SMAs, MACD negative)
  • Decreasing volume and high short‑term volatility
  • Proximity to support level with limited upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward PE of 11.6 indicating cheap earnings expectations
  • Low price‑to‑book and price‑to‑sales ratios
  • Analyst consensus of Buy with sizable upside potential

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt load and negative operating cash flow
  • Structural risks in Chinese real‑estate sector
  • Diversified business lines may provide stability over time

Key Metrics & Analysis

Financial Health

Revenue Growth-34.80%
Profit Margin0.29%
P/E Ratio74.7
ROE0.21%
ROA1.15%
Debt/Equity69.92
P/B Ratio0.3
Op. Cash FlowHK$-6756331008
Free Cash FlowHK$2.4B
Industry P/E33.1

Technical Analysis

TrendBearish
RSI44.7
SupportHK$2.15
ResistanceHK$2.51
MA 20HK$2.30
MA 50HK$2.31
MA 200HK$2.34
MACDBearish
VolumeDecreasing
Fear & Greed Index80.82

Valuation

Target PriceHK$2.98
Upside/Downside33.13%
GradeUndervalued
TypeValue

Risk Assessment

Beta-0.01
Volatility58.52%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.